Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
What Anumana’s FDA-cleared pulmonary hypertension algorithm means for cardiovascular AI
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension
Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.
GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.
Merck’s WINREVAIR clears major EU hurdle with CHMP backing for WHO FC IV patients
Merck has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an expanded indication for WINREVAIR (sotatercept) in combination with other therapies for the treatment of pulmonary arterial hypertension (PAH) in adults across WHO Functional Classes II, III, and IV. The update follows pivotal […]